...
search icon
lgnd-img

Ligand Pharmaceuticals Incorporated, Common Stock

LGND

NMQ

$109.41

+$1.38

(1.28%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$2.11B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
94.32K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.03
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$67.72 L
$129.9 H
$109.41

About Ligand Pharmaceuticals Incorporated, Common Stock

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; LYTENAVA to treat Opthamology; MEKINIST for cardiology; MINNEBRO for metabolic disease; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, JZP341, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; CE-furosemide for cardiology; CE-Meloxicam for neurology; V117, CX2101A, and Sitavig for infectious disease; REV-0100, OPT-302, and Reproxalap for opthamology; Vilazodone and Topiramate Injection for CNS; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameLGNDSectorS&P500
1-Week Return3.59%2.21%2.82%
1-Month Return-10.33%-0.14%-7.12%
3-Month Return-4.56%6.53%-4.35%
6-Month Return6.43%-5.33%-0.49%
1-Year Return49.65%1.07%8.67%
3-Year Return55.52%7.73%27.18%
5-Year Return140.68%85.88%147.38%
10-Year Return128.66%96.28%168.93%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue186.42M277.13M196.25M131.31M167.13M[{"date":"2020-12-31","value":67.27,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":70.81,"profit":true},{"date":"2023-12-31","value":47.38,"profit":true},{"date":"2024-12-31","value":60.31,"profit":true}]
Cost of Revenue30.42M62.18M52.83M35.05M11.07M[{"date":"2020-12-31","value":48.92,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":84.96,"profit":true},{"date":"2023-12-31","value":56.37,"profit":true},{"date":"2024-12-31","value":17.81,"profit":true}]
Gross Profit156.00M214.96M143.42M96.27M156.06M[{"date":"2020-12-31","value":72.57,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":66.72,"profit":true},{"date":"2023-12-31","value":44.78,"profit":true},{"date":"2024-12-31","value":72.6,"profit":true}]
Gross Margin83.68%77.56%73.08%73.31%93.37%[{"date":"2020-12-31","value":89.62,"profit":true},{"date":"2021-12-31","value":83.07,"profit":true},{"date":"2022-12-31","value":78.27,"profit":true},{"date":"2023-12-31","value":78.51,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses147.27M136.06M140.38M84.32M178.66M[{"date":"2020-12-31","value":82.43,"profit":true},{"date":"2021-12-31","value":76.15,"profit":true},{"date":"2022-12-31","value":78.57,"profit":true},{"date":"2023-12-31","value":47.2,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income8.55M78.89M(25.50M)11.94M(22.61M)[{"date":"2020-12-31","value":10.84,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-32.33,"profit":false},{"date":"2023-12-31","value":15.14,"profit":true},{"date":"2024-12-31","value":-28.65,"profit":false}]
Total Non-Operating Income/Expense(55.73M)(50.39M)33.22M57.99M30.14M[{"date":"2020-12-31","value":-96.09,"profit":false},{"date":"2021-12-31","value":-86.88,"profit":false},{"date":"2022-12-31","value":57.28,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":51.97,"profit":true}]
Pre-Tax Income(10.54M)47.30M36.01M63.66M2.52M[{"date":"2020-12-31","value":-16.55,"profit":false},{"date":"2021-12-31","value":74.3,"profit":true},{"date":"2022-12-31","value":56.57,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":3.96,"profit":true}]
Income Taxes(7.55M)(10.29M)41.23M9.84M(6.55M)[{"date":"2020-12-31","value":-18.32,"profit":false},{"date":"2021-12-31","value":-24.95,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":23.87,"profit":true},{"date":"2024-12-31","value":-15.89,"profit":false}]
Income After Taxes(2.98M)57.59M(5.22M)53.82M9.07M[{"date":"2020-12-31","value":-5.18,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-9.06,"profit":false},{"date":"2023-12-31","value":93.46,"profit":true},{"date":"2024-12-31","value":15.75,"profit":true}]
Income From Continuous Operations(2.98M)57.59M(5.22M)21.10M(4.03M)[{"date":"2020-12-31","value":-5.18,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-9.06,"profit":false},{"date":"2023-12-31","value":36.64,"profit":true},{"date":"2024-12-31","value":-7,"profit":false}]
Income From Discontinued Operations(9.58M)(19.21M)(28.14M)--[{"date":"2020-12-31","value":-958300000,"profit":false},{"date":"2021-12-31","value":-1921500000,"profit":false},{"date":"2022-12-31","value":-2814200000,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(2.98M)57.14M(5.22M)52.15M(4.03M)[{"date":"2020-12-31","value":-5.22,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-9.13,"profit":false},{"date":"2023-12-31","value":91.28,"profit":true},{"date":"2024-12-31","value":-7.06,"profit":false}]
EPS (Diluted)4.556.424.286.105.71[{"date":"2020-12-31","value":70.87,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":66.67,"profit":true},{"date":"2023-12-31","value":95.02,"profit":true},{"date":"2024-12-31","value":88.94,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

LGND
Cash Ratio 6.90
Current Ratio 8.93
Quick Ratio 8.55

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

LGND
ROA (LTM) 1.66%
ROE (LTM) -0.53%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

LGND
Debt Ratio Lower is generally better. Negative is bad. 0.12
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.88

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

LGND
Trailing PE NM
Forward PE 17.95
P/S (TTM) 12.61
P/B 2.54
Price/FCF 76
EV/R 11.11
EV/Ebitda 45.54
PEG 1.53

FAQs

What is Ligand Pharmaceuticals Incorporated share price today?

Ligand Pharmaceuticals Incorporated (LGND) share price today is $109.41

Can Indians buy Ligand Pharmaceuticals Incorporated shares?

Yes, Indians can buy shares of Ligand Pharmaceuticals Incorporated (LGND) on Vested. To buy Ligand Pharmaceuticals Incorporated from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in LGND stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Ligand Pharmaceuticals Incorporated be purchased?

Yes, you can purchase fractional shares of Ligand Pharmaceuticals Incorporated (LGND) via the Vested app. You can start investing in Ligand Pharmaceuticals Incorporated (LGND) with a minimum investment of $1.

How to invest in Ligand Pharmaceuticals Incorporated shares from India?

You can invest in shares of Ligand Pharmaceuticals Incorporated (LGND) via Vested in three simple steps:

  • Click on Sign Up or Invest in LGND stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Ligand Pharmaceuticals Incorporated shares
What is Ligand Pharmaceuticals Incorporated 52-week high and low stock price?

The 52-week high price of Ligand Pharmaceuticals Incorporated (LGND) is $129.9. The 52-week low price of Ligand Pharmaceuticals Incorporated (LGND) is $67.72.

What is Ligand Pharmaceuticals Incorporated price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Ligand Pharmaceuticals Incorporated (LGND) is 2.54

What is the Market Cap of Ligand Pharmaceuticals Incorporated?

The market capitalization of Ligand Pharmaceuticals Incorporated (LGND) is $2.11B

What is Ligand Pharmaceuticals Incorporated’s stock symbol?

The stock symbol (or ticker) of Ligand Pharmaceuticals Incorporated is LGND

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top